Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) traded up 3.1% during mid-day trading on Friday . The company traded as high as $4.89 and last traded at $4.80. 18,008 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,049,645 shares. The stock had previously closed at $4.65.
Virios Therapeutics Stock Performance
The company has a market cap of $95.52 million, a price-to-earnings ratio of -18.37 and a beta of 1.58. The business's 50 day moving average price is $4.84 and its 200-day moving average price is $5.11.
Virios Therapeutics Company Profile
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Stories
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
